Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Cosman

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 21, 2012
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisSteven Boonen, Richard Eastell, Guoqin Su, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Clinical Therapeutics|May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) studyRonald Emkey, Pierre D Delmas, Michael Bolognese, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 17, 2024
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective AnalysisLaila Tabatabai, Felicia Cosman, Jeffrey R Curtis, et al.
Mayo Clinic Proceedings|February 6, 2017
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend TrialFelicia Cosman, Paul D Miller, Gregory C Williams, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 4, 2010
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosisFelicia Cosman, Erik Fink Eriksen, Chris Recknor, et al.
The Journal of Clinical Endocrinology and Metabolism|March 12, 2003
Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatmentBarbara M Misof, Paul Roschger, Felicia Cosman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 22, 2011
Abnormal microarchitecture and stiffness in postmenopausal women with ankle fracturesEmily M Stein, X Sherry Liu, Thomas L Nickolas, et al.
Journal of Cellular Biochemistry|February 22, 2005
Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblastsDavid W Dempster, Christine E Hughes-Begos, Katarina Plavetic-Chee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 16, 2021
Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture TrialSocrates Papapoulos, Henry Bone, Felicia Cosman, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 21, 2012
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisSteven Boonen, Richard Eastell, Guoqin Su, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Clinical Therapeutics|May 19, 2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) studyRonald Emkey, Pierre D Delmas, Michael Bolognese, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 17, 2024
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective AnalysisLaila Tabatabai, Felicia Cosman, Jeffrey R Curtis, et al.
Mayo Clinic Proceedings|February 6, 2017
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend TrialFelicia Cosman, Paul D Miller, Gregory C Williams, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 4, 2010
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosisFelicia Cosman, Erik Fink Eriksen, Chris Recknor, et al.
The Journal of Clinical Endocrinology and Metabolism|March 12, 2003
Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatmentBarbara M Misof, Paul Roschger, Felicia Cosman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 22, 2011
Abnormal microarchitecture and stiffness in postmenopausal women with ankle fracturesEmily M Stein, X Sherry Liu, Thomas L Nickolas, et al.
Journal of Cellular Biochemistry|February 22, 2005
Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblastsDavid W Dempster, Christine E Hughes-Begos, Katarina Plavetic-Chee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 16, 2021
Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture TrialSocrates Papapoulos, Henry Bone, Felicia Cosman, et al.
Pageof 12